Deep Learning-Based Drug Discovery and Molecular Analysis Accelerating the Future of Medicine

With the help of deep learning integration in drug discovery and molecular analysis, the pharmaceutical industry is facing the problem of traditional approaches. This paper outlines the ground for a deep learning approach to improve the speed of drug discovery and molecular investigations concerning DTI prediction, new drug design, multi-omics integration, and drug repositioning. To this end, the framework uses state-of-the-art architectures, for example convolutions neural networks (CNNs), transformers, generative models to identify new compounds and possible therapeutic use with very high accuracy. The integration of CNN and attention significantly improves the prediction accuracy of drug-target interaction reaching 93% and AUROC of 96%. The synthesizability of the generated molecules in de novo drug design using the hybrid VAE-GAN model is 80.8% compared to the standalone models. When using multiparameters for biomarker discovery, the sensitivity improved to 93.4%, specificity to 91.8% and accuracy to 92.6% proving the benefits of comparing genomic, transcriptomic and proteomic data. Although lower than that of new chemical entities, 9.1% utilization of drugs for new therapies, especially for neurodegenerative diseases, illustrates that drug repurposing strategies work well. Based on this taxonomy, the revolutionary possibilities of deep learning in the more rapid advancement of drug discovery with the lower costs and time horizons that such an advance entails is made evident. Specifically, the results highlight the ability of the devised framework for considering actual case studies in terms of compound innovation, patient profiling and therapeutic development.